GSK announced that it has taken a ~25% stake in a new spin out. This is a terrific way to create new companies and advance more molecules into the clinic, especially for indications like tinnitus, which are not typically ares of interest for big pharma.
These are NCEs from GSK’s portfolio, so they have a head start in the sense that there is likely a solid Preclinical package in place. Plus, the initial executive team are experienced drug developers. Lastly, the company has secured ￡20 million from venture capital investors. This is an unusually large amount of funding for a start up.
We need more companies like GSK to liberate molecules from their pipelines by creating new companies that will focus on their development.